Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Oral Communications

Oral Communications 8: Calcium and Bone

ea0081oc8.1 | Oral Communications 8: Calcium and Bone | ECE2022

Effectiveness of anti-resorptive drugs on risk of vertebral fractures in women receiving aromatase inhibitors: a prospective study in real-life clinical practice

Mazziotti Gherardo , Vena Walter , Pigni Stella , Carrone Flaminia , Pedersini Rebecca , Cosentini Deborah , Torrisi Rosalba , Birtolo Maria Francesca , Maida Giulia , Berruti Alfredo , Lania Andrea

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

ea0081oc8.2 | Oral Communications 8: Calcium and Bone | ECE2022

SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: a Danish population-based cohort study

Al-Mashhadi Zheer Kejlberg , Viggers Rikke , Starup-Linde Jakob , Vestergaard Peter , Gregersen Soren

Background: Type 2 diabetes mellitus (T2D) is associated with an increased risk of fractures. Research on the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is scarce and unsettled. We aimed to investigate the risk of major osteoporotic fractures (MOF) – i.e., hip, vertebral, humerus, and forearm fractures – with SGLT2 inhibitors compared to glucagon-like peptide 1 (GLP-1) receptor agonists when either is used in combination with metformin.<p class...

ea0081oc8.3 | Oral Communications 8: Calcium and Bone | ECE2022

Impact of preoperative zoledronic acid on hungry bone syndrome and bone health indices in patients with primary hyperparathyroidism after curative parathyroidectomy: a randomized controlled trial

Gautam Akanksha , Bhadada Sanjay , Bhansali Anil , Dahiya Divya , Behera Arunanshu , Saikia Uma Nahar , Sood Ashwani , Singh Tulika

Background: In individuals with primary hyperparathyroidism (PHPT), the utility of preoperative bisphosphonate administration in prevention of post-curative-parathyroidectomy hungry bone syndrome (HBS) and effects on long-term bone accrual are uncertain.Objectives: To estimate the effect of preoperative administration of single infusion of zoledronic acid (ZA) on occurrence of HBS and gain in bone mineral density (BMD) at one year in individuals with PHP...

ea0081oc8.4 | Oral Communications 8: Calcium and Bone | ECE2022

Is the “rebound phenomenon” following Denosumab discontinuation a risk factor for Zoledronic acid acute phase adverse reactions?

Zampogna Marta , Grassi Giorgia , Ghielmetti Alberto , Palmieri Serena , Arosio Maura , Vainicher Cristina Eller

Background: Zoledronic acid (ZOL) administration may cause acute phase adverse reactions (APR), which manifest with fever, malaise, bone and muscular pain, headache and/or gastrointestinal disturbances. Previous data suggest that high N-terminal propeptide of type 1 collagen (P1NP) and low 25, OH-vitaminD (VitD) levels are associated with higher incidence of APR, while the previous use of bisphosphonates is a protective factor. Lately, ZOL has been frequently used to mitigate ...

ea0081oc8.5 | Oral Communications 8: Calcium and Bone | ECE2022

Key4OI: Development and implementation of a standard set of outcome measures for osteogenesis imperfecta

Franken Anton , Mekking Dagmar

Key4OI : Development and implementation of a Standard set of Outcome measures for Osteogenesis Imperfecta. Osteogenesis Imperfecta (OI) is a genetic disorder also known as ‘brittle bone disease’. The clinical manifestation of OI shows a wide variation. Therefore, care for patients with OI requires an interdisciplinary approach. The effectiveness of particular interventions and treatment protocols of interdisciplinary teams is not clear due to a non-standardized and w...

ea0081oc8.6 | Oral Communications 8: Calcium and Bone | ECE2022

Dose-range analysis of the effects of the long-acting parathyroid hormone analog AZP-3601 versus PTH(1-34) delivered by daily injection or continuous infusion on blood calcium levels and bone metabolism in thyroparathyroidectomized (TPTX) rats

Aksu Cagri , Culler Michael D , Gardella Thomas

AZP-3601, a long-acting PTH/PTHrP(1-36) analog, is a candidate new treatment option for hypoparathyroidism (HP). As compared to conventional PTH(1-34), AZP-3601 binds with higher affinity to the R0 conformation of the PTH-1 receptor, resulting in prolonged signaling and sustained elevations in blood calcium (Ca++) in vivo, despite a very short circulating half-life. We assessed whether repeated injection of AZP-3601 into TPTX rats at doses aimed to normalize serum C...